34. 神経線維腫症 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 165 / 薬物数 : 189 - (DrugBank : 83) / 標的遺伝子数 : 93 - 標的パスウェイ数 : 209

薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
1064NM laser
   Massachusetts General Hospital
      2021   Phase 1   NCT04730583   United States
1064NM ND:YAG laser
   Massachusetts General Hospital
      2024   Phase 1   NCT06300502   United States
      2024   Phase 1   NCT06132165   United States
2-amino-4-(methyl[11C]sulfanyl)butanoic acid
   Guys' and St. Thomas' NHS Foundation Trust
      2011   -   EUCTR2010-019759-23-GB   United Kingdom
755NM alexandrite laser
   Massachusetts General Hospital
      2024   Phase 1   NCT06300502   United States
      2024   Phase 1   NCT06132165   United States
      2021   Phase 1   NCT04730583   United States
89ZR-bevacizumab
   Leiden University Medical Center
      2021   Phase 2   EUCTR2020-000156-35-NL   Netherlands
Abemaciclib
   National Cancer Institute (NCI)
      2021   Phase 1/Phase 2   NCT04750928   United States
Acetaminophen
   AstraZeneca
      2018   Phase 1   NCT03649165   United States
Acetylcysteine
   Children's Hospital Medical Center, Cincinnati
      2019   Phase 2   NCT04481035   United States
Afinitor
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2011-002228-42-FR   France
   New York University School of Medicine
      2011   Phase 2   NCT01419639   United States
AL2846 capsules
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2021   Phase 1/Phase 2   NCT05011019   China
Aminolevulinic acid
   Donald Basel
      2016   Phase 2   NCT02728388   United States
AMN107
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland
Antigen-specific T cells cart/CTL and dcvac
   Shenzhen Geno-Immune Medical Institute
      2019   Phase 1/Phase 2   NCT04085159   China
APG-115
   AeRang Kim
      2025   Phase 1/Phase 2   NCT06735820   United States
AR-42
   Massachusetts Eye and Ear Infirmary
      2015   Early Phase 1   NCT02282917   United States
Asclera
   Massachusetts General Hospital
      2024   Phase 1   NCT06300502   United States
      2022   Phase 1   NCT06120036   United States
Aspirin
   Massachusetts Eye and Ear Infirmary
      2018   Phase 2   NCT03079999   United States
Axitinib
   NYU Langone Health
      2014   Phase 2   NCT02129647   United States
Azacitidine
   Therapeutic Advances in Childhood Leukemia Consortium
      2024   Phase 1/Phase 2   NCT05849662   United States
AZD2014
   Massachusetts General Hospital
      2016   Phase 2   NCT02831257   United States
AZD6244
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2022   Phase 3   EUCTR2020-005607-39-PL   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-ES   Poland;Russian Federation;Spain;United States
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-FR   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   National Cancer Institute (NCI)
      2011   Phase 1/Phase 2   NCT01362803   United States
Bevacizumab
   Kiyoshi Saito
      2019   Phase 2   JPRN-jRCT2080224914   Japan
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
   National Cancer Institute (NCI)
      2010   Phase 2   NCT01207687   United States
   Northwestern University
      2010   Phase 2   NCT01125046   United States
   Sarcoma Alliance for Research through Collaboration
      2012   Phase 2   NCT01661283   United States
   Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of Medicine
      2018   -   ChiCTR1800016040   China
   University of Alabama at Birmingham
      2013   Phase 2   NCT01767792   United States
Bevacizumab zirconium ZR-89
   Leiden University Medical Center
      2022   -   NCT05685836   Netherlands
      2021   Phase 2   EUCTR2020-000156-35-NL   Netherlands
Binimetinib
   University of Alabama at Birmingham
      2017   Phase 2   NCT03231306   United States
Biopsy
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000036770   China
Biospecimen collection
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2010   Phase 1/Phase 2   NCT01089101   United States
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06147414   France
Bone marrow aspiration and biopsy
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03190915   United States
Bony toxicity
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
Brigatinib
   Scott R. Plotkin, MD, PhD
      2020   Phase 2   NCT04374305   United States
Busulfan
   Masonic Cancer Center, University of Minnesota
      2023   Phase 2   NCT05735717   United States
Cabozantinib
   University of Alabama at Birmingham
      2014   Phase 2   NCT02101736   United States
Cabozantinib oral tablet
   Girish Dhall, MD
      2025   Phase 1   NCT06502171   United States
Carboplatin
   Children's Oncology Group
      2006   Phase 1   NCT00352495   Canada;United States
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2020   Phase 3   NCT03871257   Canada;Puerto Rico;United States
Cediranib maleate
   National Cancer Institute (NCI)
      2006   Phase 2   NCT00326872   United States
Celecoxib
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States
Cetuximab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Cholecalciferol
   University of Utah
      2017   Phase 2   NCT01968590   Canada;Germany;United States
Conventional surgery
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States
Crizotinib
   Medical University of Warsaw
      2023   Phase 2   EUCTR2021-005770-26-PL   Poland
   University of Alabama at Birmingham
      2020   Phase 2   NCT04283669   United States
Curcumin
   Masonic Cancer Center, University of Minnesota
      2022   Phase 1   NCT05363267   United States
Cytarabine
   Therapeutic Advances in Childhood Leukemia Consortium
      2024   Phase 1/Phase 2   NCT05849662   United States
Dabrafenib
   Novartis Pharmaceuticals
      2019   Phase 4   NCT03975829   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
   Pediatric Brain Tumor Consortium
      2020   Phase 1/Phase 2   NCT04201457   United States
Deoxycholic acid
   Massachusetts General Hospital
      2024   Phase 1   NCT06132165   United States
Dexmedetomidine
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States
Diclofenac sodium
   Fundação Educacional Serra dos Órgãos
      2017   Phase 2   NCT03090971   Brazil
Doxorubicin hydrochloride
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States
Doxycycline
   Massachusetts Eye and Ear Infirmary
      2022   Phase 1/Phase 2   NCT05521048   United States
Endostatin
   Beijing Tiantan Hospital
      2014   Phase 2   NCT02104323   China
Etoposide
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States
Everolimus
   New York University School of Medicine
      2011   Phase 2   NCT01419639   United States
   Novartis Pharmaceuticals
      2012   Phase 2   NCT01365468   Israel
      -   Phase 4   EUCTR2016-001563-36-Outside-EU/EEA   Israel
   Sarcoma Alliance for Research through Collaboration
      2012   Phase 2   NCT01661283   United States
   The University of Texas Health Science Center, Houston
      2015   Phase 2   NCT02332902   United States
EVérolimus
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2011-002228-42-FR   France
FCN-159
   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
      2023   Phase 1;Phase 2   EUCTR2021-001572-42-IT   China;France;Italy;Poland;Spain;United States
      2021   Phase 1/Phase 2   NCT04954001   China;Spain;United States
Filgrastim
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States
Fludarabine
   Masonic Cancer Center, University of Minnesota
      2023   Phase 2   NCT05735717   United States
   Therapeutic Advances in Childhood Leukemia Consortium
      2024   Phase 1/Phase 2   NCT05849662   United States
Fludeoxyglucose F 18
   Children's Hospital of Philadelphia
      2002   -   NCT00060008   United States
Frameshift array blood sample test
   Children's National Research Institute
      2019   -   NCT04212351   United States
Gadolinium contrast
   Washington University School of Medicine
      2013   -   NCT02584413   United States
Gadopentetate dimeglumine
   Children's Hospital of Philadelphia
      2002   -   NCT00060008   United States
Genetic analysis
   University Hospital, Toulouse
      2009   -   NCT02422732   France
Gleevec
   Indiana University
      2006   Phase 2   NCT01673009   United States
   Kent Robertson
      2012   Phase 1/Phase 2   NCT01140360   United States
Glivec 100 MG comprimidos recubiertos CON PELícula
   HOSPITAL SANT JOAN DE DÉU
      2010   -   EUCTR2009-016922-15-ES   Spain
Glivec 400 MG comprimidos recubiertos CON PELícula
   HOSPITAL SANT JOAN DE DÉU
      2010   -   EUCTR2009-016922-15-ES   Spain
Glycopyrrolate
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States
HL-085
   Shanghai Kechow Pharma, Inc.
      2021   Phase 2   NCT05331105   China
HLX-1502
   Healx Limited
      2025   Phase 2   NCT06541847   United States
Hydroxychloroquine
   Pediatric Brain Tumor Consortium
      2020   Phase 1/Phase 2   NCT04201457   United States
Icotinib
   Li Peng
      2016   Phase 2   NCT02934256   China
Ifosfamide
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States
Imatinib
   HOSPITAL SANT JOAN DE DÉU
      2010   -   EUCTR2009-016922-15-ES   Spain
Imatinib mesylate
   Indiana University
      2018   Phase 2   NCT03688568   United States
   St. Justine's Hospital
      2014   Phase 2   NCT02177825   Canada
Imiquimod 5% cream
   Massachusetts General Hospital
      2009   Phase 1   NCT00865644   United States
Koselugo 10MG
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-ES   Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-FR   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Koselugo 25MG
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-ES   Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-FR   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Kybella
   Massachusetts General Hospital
      2024   Phase 1   NCT06300502   United States
      2022   Phase 1   NCT06120036   United States
      2021   Phase 1   NCT04730583   United States
Laboratory biomarker analysis
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
   National Cancer Institute (NCI)
      2017   Phase 2   NCT02839720   United States
      2015   Phase 1   NCT02415153   United States
      2010   Phase 2   NCT01207687   United States
Lamotrigin beta
   Technische Universität München, Fakultät für Medizin
      2018   Phase 2   EUCTR2016-005022-10-DE   Germany
Lamotrigine
   Erasmus Medical Center
      2014   Phase 2/Phase 3   NCT02256124   Belgium;Netherlands;Spain
Lamotrigine dispers
   Erasmus MC
      2018   Phase 2   EUCTR2013-003405-26-DK   Belgium;Denmark;Netherlands;Spain
      2017   Phase 2   EUCTR2013-003405-26-ES   Belgium;Netherlands;Spain
      2015   Phase 2   EUCTR2013-003405-26-BE   Belgium;Denmark;Netherlands;Spain
      2014   -   EUCTR2013-003405-26-NL   Netherlands
Lapatinib
   New York University School of Medicine
      2009   Phase 2   NCT00973739   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2009   Early Phase 1   NCT00863122   United States
Lenalidomide
   National Cancer Institute (NCI)
      2012   Phase 2   NCT01553149   Australia;Canada;New Zealand;United States
Levetiracetam
   Masonic Cancer Center, University of Minnesota
      2023   Phase 2   NCT05735717   United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 1
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 2
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 3
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States
Lidocaine 1% injectable solution
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States
Lovastatin
   Technische Universität München, Fakultät für Medizin
      2018   Phase 2   EUCTR2016-005022-10-DE   Germany
   University of Alabama at Birmingham
      2009   Phase 2   NCT00853580   Australia;United States
   University of California, Los Angeles
      2009   Phase 1   NCT00352599   United States
   Vanderbilt University
      2016   Phase 2   NCT02964884   United States
Lovastatin 60 MG
   University of Coimbra
      2019   -   NCT03826940   Portugal
Magnetic resonance imaging
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2020   Phase 3   NCT03871257   Canada;Puerto Rico;United States
   Washington University School of Medicine
      2013   -   NCT02584413   United States
Mekinist
   ErasmusMC
      2019   Phase 2   EUCTR2019-001317-16-NL   Netherlands
   VO Barnmedicin, Skånes University Hospital
      2018   Phase 2   EUCTR2018-001846-32-SE   Sweden
Melphalan
   Masonic Cancer Center, University of Minnesota
      2023   Phase 2   NCT05735717   United States
Methionine
   Guys' and St. Thomas' NHS Foundation Trust
      2011   -   EUCTR2010-019759-23-GB   United Kingdom
Methotrexate
   Children's Hospital of Philadelphia
      2001   Phase 2   NCT00030264   United States
Methylphenidate
   Hospices Civils de Lyon
      2004   Phase 4   NCT00169611   France
Mirdametinib
   Johns Hopkins University
      2024   Phase 1/Phase 2   NCT06159166   United States
   SpringWorks Therapeutics, Inc.
      2022   -   NCT05028166   -
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
   SpringWorks Therapeutics, Inc.
      2019   Phase 2   NCT03962543   United States
MRI, FDG-PET/CT scans
   National Cancer Institute (NCI)
      2014   Phase 1   NCT02211768   United States
N-acetyl cysteine
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 2   NCT04481048   United States
NAC
   Children's Hospital Medical Center, Cincinnati
      2019   Phase 2   NCT04481035   United States
Neratinib
   Scott R. Plotkin, MD, PhD
      2020   Phase 2   NCT04374305   United States
Neuropsychological assessments
   University Hospital, Toulouse
      2009   -   NCT02422732   France
Nexavar
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2011-001789-16-GB   United Kingdom
NFX-179 GEL
   NFlection Therapeutics, Inc.
      2021   Phase 2   NCT05005845   United States
      2020   Phase 2   NCT04435665   United States
Nilotinib
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2010-023508-28-GB   United Kingdom
Nilotinib hydrochloride monohydrate
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland
Nitrous oxide
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States
NPC-12G GEL
   Nobelpharma
      2020   Phase 3   NCT04461886   Japan
Olive OIL
   Masonic Cancer Center, University of Minnesota
      2022   Phase 1   NCT05363267   United States
Oncolytic measles virus encoding thyroidal sodium iodide symporter
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
Other academic sham tutoring
   Vanderbilt University
      2016   Phase 2   NCT02964884   United States
Part 1 levulan injection
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States
Part 1 levulan surface application twice with microneedling
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States
PAS-004 tablets
   Pasithea Therapeutics Corp.
      2025   Phase 1   NCT06961565   Australia
PD-0325901
   University of Alabama at Birmingham
      2014   Phase 2   NCT02096471   United States
PEG-interferon alpha-2B
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States
Pharmacodynamics
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
Pharmacological study
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
   National Cancer Institute (NCI)
      2015   Phase 1   NCT02415153   United States
      2012   Phase 2   NCT01553149   Australia;Canada;New Zealand;United States
Pirfenidone
   Mayo Clinic
      2000   Phase 2   NCT00754780   -
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076102   United States
      2002   Phase 1   NCT00053937   United States
Polidocanol
   Massachusetts General Hospital
      2024   Phase 1   NCT06132165   United States
Poly iclc
   University of Alabama at Birmingham
      2022   Phase 2   NCT04544007   United States
Pomalidomide
   National Cancer Institute (NCI)
      2015   Phase 1   NCT02415153   United States
Propofol
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States
PTC299
   PTC Therapeutics
      2009   Phase 2   NCT00911248   United States
QOL assessment, neuropsychological
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
Quality-OF-life assessment
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2020   Phase 3   NCT03871257   Canada;Puerto Rico;United States
      2010   Phase 2   NCT01207687   United States
Questionnaire administration
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2020   Phase 3   NCT03871257   Canada;Puerto Rico;United States
RAD001
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2011-002228-42-FR   France
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 2   NCT01490476   France
   NYU Langone Health
      2013   Early Phase 1   NCT01880749   United States
   New York University School of Medicine
      2011   Phase 2   NCT01419639   United States
   Novartis Pharmaceuticals
      2012   Phase 2   NCT01365468   Israel
      -   Phase 4   EUCTR2016-001563-36-Outside-EU/EEA   Israel
RAD001, everolimus
   Jonsson Comprehensive Cancer Center
      2015   Phase 2   NCT01345136   United States
RAD001: everolimus
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2   NCT01412892   France
Radiation therapy
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States
Radiographic evaluation
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
Ranibizumab
   Massachusetts General Hospital
      2008   Phase 0   NCT00657202   United States
Rapamycin
   Department of Dermatology Graduate School of Medicine, Osaka University
      2014   Phase 2,3   JPRN-UMIN000015081   Japan
Reading tutoring intervention
   Vanderbilt University
      2016   Phase 2   NCT02964884   United States
REC-2282
   Recursion Pharmaceuticals Inc.
      2022   Phase 2/Phase 3   NCT05130866   United States
Rituximab
   Masonic Cancer Center, University of Minnesota
      2023   Phase 2   NCT05735717   United States
Saline solution
   Fundação Educacional Serra dos Órgãos
      2017   Phase 2   NCT03090971   Brazil
Selumetinib
   AeRang Kim
      2025   Phase 1/Phase 2   NCT06735820   United States
   AstraZeneca
      2023   Phase 2   NCT05825365   China
      2021   Phase 1   NCT05101148   Poland;Russian Federation;Spain;United States
      2021   Phase 3   NCT04924608   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 1   NCT04590235   China
      2020   Phase 1   NCT04495127   Japan
      2017   -   NCT03259633   United States
   AstraZeneca KK
      2020   Phase 1   JPRN-jRCT2080225326   Japan;North America
   Children's Hospital Medical Center, Cincinnati
      2017   Phase 2   NCT03095248   United States
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2019   Phase 1/Phase 2   NCT03326388   United Kingdom
   Kobayashi Hiroshi
      2023   Phase 1-2   JPRN-jRCT2071220074   Germany;Italy;Japan;Netherland;Russia;Spain;USA
      2022   Phase 3   JPRN-jRCT2041210036   Australia;Brasil;Canada;China;France;Germany;Italy;Japan;Poland;Russia;Spain;UK;USA
   National Cancer Institute (NCI)
      2016   Phase 2   NCT02407405   United States
      2015   Phase 2   NCT02644512   United States
      2010   Phase 1/Phase 2   NCT01089101   United States
   Sarcoma Alliance for Research through Collaboration
      2019   Phase 2   NCT03433183   United States
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000036770   China
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2024   Phase 2   NCT06621082   -
      2024   Phase 2   NCT06620354   -
   University of Alabama at Birmingham
      2025   Phase 2   NCT06188741   -
      2017   Phase 2   NCT03105258   United States
   West China Hospital
      2025   Phase 2   NCT06763315   China
Selumetinib (AZD6244 HYD sulfate) 25MG/M2
   National Cancer Institute (NCI)
      2017   Phase 2   NCT03109301   United States
Selumetinib (AZD6244 HYD sulfate) 50MG/dose
   National Cancer Institute (NCI)
      2017   Phase 2   NCT03109301   United States
Selumetinib 10MG capsule
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   AstraZeneca AB
      2022   Phase 3   EUCTR2020-005607-39-PL   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-ES   Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-FR   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib 25MG capsule
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   AstraZeneca AB
      2022   Phase 3   EUCTR2020-005607-39-PL   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-ES   Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-FR   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib capsule formulation
   AstraZeneca
      2022   Phase 1/Phase 2   NCT05309668   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib capsules 10MG
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib capsules 25MG
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib granule formulation
   AstraZeneca
      2022   Phase 1/Phase 2   NCT05309668   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib granules IN sprinkle capsules FOR opening 5 MG
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
Selumetinib granules IN sprinkle capsules FOR opening 7.5 MG
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib HYD-sulfate
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States
      2022   Phase 3   EUCTR2020-005607-39-PL   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-FR   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib HYD-sulphate
   Great Ormond Street Hospital
      2018   Phase 1;Phase 2   EUCTR2017-002635-41-GB   United Kingdom
Selumetinib oral capsule
   Girish Dhall, MD
      2025   Phase 1   NCT06502171   United States
Selumetinib sulfate
   AstraZeneca AB
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States
      2021   Phase 1   EUCTR2020-005648-52-ES   Poland;Russian Federation;Spain;United States
   Great Ormond Street Hospital
      2018   Phase 1;Phase 2   EUCTR2017-002635-41-GB   United Kingdom
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2020   Phase 3   NCT03871257   Canada;Puerto Rico;United States
      2017   Phase 2   NCT02839720   United States
Sevoflurane
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States
Simvastatin
   Erasmus MC - Department of Pediatrics
      2009   -   EUCTR2009-010965-22-NL   Netherlands
Simvastatin 20MG/5ML oral suspension
   Central Manchester University Hospitals NHS Foundation Trust
      2013   Phase 2   EUCTR2012-005742-38-GB   United Kingdom
Single photon emission computed tomography
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
Sirolimus
   Osaka University Hospital
      2016   Phase 2   JPRN-UMIN000021030   Japan
   Sarcoma Alliance for Research through Collaboration
      2019   Phase 2   NCT03433183   United States
   University of Alabama at Birmingham
      2008   Phase 2   NCT00652990   United States
      2008   Phase 2   NCT00634270   United States
Skincerity plus sirolimus/rapamycin
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States
Skinercity plus sirolimus/rapamycin
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States
Sodium chloride
   Kiyoshi Saito
      2019   Phase 2   JPRN-jRCT2080224914   Japan
Sorafenib
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2011-001789-16-GB   United Kingdom
ST002
   Cancer Institute and Hospital, Chinese Academy of Medical Sciences
      2025   -   NCT06834438   China
Sunitinib
   Memorial Sloan Kettering Cancer Center
      2007   Phase 2   NCT00589784   United States
Sutent®/sunitinib
   Indiana University
      2012   Phase 2   NCT01402817   United States
Tarceva and rapamycin
   Roger Packer
      2007   Phase 1   NCT00901849   United States
Tasigna
   Indiana University
      2011   Early Phase 1   NCT01275586   United States
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2010-023508-28-GB   United Kingdom
Tasigna 150MG
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland
Tasigna 200MG
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland
Tasigna 50 MG
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland
Temozolomide
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States
Temsirolimus
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Test group (group A): FCN-159 8 MG, orally, once daily
   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
      2023   Phase 3   NCT05913037   China
Tipifarnib
   National Cancer Institute (NCI)
      2001   Phase 2   NCT00021541   Germany;United States
Toxicity, pharmacokinetics
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States
Trametinib
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03190915   United States
   Novartis Pharmaceuticals
      2019   Phase 4   NCT03975829   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
   Pediatric Brain Tumor Consortium
      2020   Phase 1/Phase 2   NCT04201457   United States
   Region Skane
      2019   Phase 2   NCT03741101   Sweden
   Therapeutic Advances in Childhood Leukemia Consortium
      2024   Phase 1/Phase 2   NCT05849662   United States
   University of California, San Francisco
      2018   Phase 2   NCT03232892   United States
Treatment A
   AstraZeneca
      2018   Phase 1   NCT03649165   United States
Treatment B
   AstraZeneca
      2018   Phase 1   NCT03649165   United States
Treatment C
   AstraZeneca
      2018   Phase 1   NCT03649165   United States
Treatment D
   AstraZeneca
      2018   Phase 1   NCT03649165   United States
Ultrasound imaging
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States
Unknown
   Leiden University Medical Center
      2021   Phase 2   EUCTR2020-000156-35-NL   Netherlands
Valproic acid
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Vehicle GEL
   NFlection Therapeutics, Inc.
      2021   Phase 2   NCT05005845   United States
      2020   Phase 2   NCT04435665   United States
Vinblastine
   Children's Hospital of Philadelphia
      2001   Phase 2   NCT00030264   United States
Vinblastine sulfate
   Children's Oncology Group
      2006   Phase 1   NCT00352495   Canada;United States
Vinblastine sulphate
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland
Vincristine sulfate
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States
      2020   Phase 3   NCT03871257   Canada;Puerto Rico;United States
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States
Votubia
   Novartis Pharmaceuticals
      -   Phase 4   EUCTR2016-001563-36-Outside-EU/EEA   Israel
Xalkori
   Medical University of Warsaw
      2023   Phase 2   EUCTR2021-005770-26-PL   Poland